IBt Bebig Changes Its Name to Eckert & Ziegler BEBIG
(Thomson Reuters ONE) -
IBt Bebig Changes Its Name to Eckert & Ziegler BEBIG
June 29, 2011
Seneffe, Belgium, June 29, 2011, IBt Bebig (Reuters: IBTH.BR - Bloomberg: IBTB
BB), a global leader in brachytherapy, announced today that it has changed its
corporate name to Eckert & Ziegler BEBIG S.A.
As of July 1, 2011, the company will trade on the Euronext exchange under the
new ticker symbol EZBG.
The name change was recommended and approved during the Extraordinary General
Meeting held on June 6, 2011 in Seneffe.
The new name, Eckert & Ziegler BEBIG S.A., underlines the company's affiliation
with the Eckert & Ziegler Group, one of the world's largest providers of isotope
technology for medical, scientific, and industrial purposes. The Eckert &
Ziegler Group has four business segments, Radiation Therapy,
Radiopharmaceuticals, Isotope Products, and Environmental Services, all operated
through its subsidiaries. With over 30 years' experience in the radiation
therapy business, Eckert & Ziegler BEBIG S.A. will continue to drive the Group's
leadership position.
"The vision behind the renaming has been to reinforce the fact that we are a
part of a leading group with a well recognized name: Eckert & Ziegler. This
supports our strategy of further worldwide expansion and our commitment to
developing and providing medical devices and products to cure cancer and enhance
the quality of life," said Dr. Edgar Löffler, Managing Director of Eckert &
Ziegler BEBIG S.A.
Cancer represents a major public health threat the world over. Radiation therapy
is already prescribed for half of all cancer cases, and trends point to
increased use. In this context, Eckert & Ziegler has set near-term objectives of
globalizing the business, accelerating innovation, strengthening its portfolio,
and ensuring supply.
Relationships with current business partners and customers will be managed
through the same channels as before. The website domain name will change
towww.bebig.eu. and all company email addresses will have the following format:
firstname.lastname(at)bebig.eu, as of July 1, 2011.
About Eckert & Ziegler BEBIG
Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group active in the medical device
segment of the health care industry.
Eckert & Ziegler BEBIG's core business is the treatment of cancer using
brachytherapy, a special form of radiation therapy.
Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company
headquarters are in Belgium, with a production facility in Germany and
subsidiaries throughout Europe and in India. In addition, Eckert & Ziegler BEBIG
has a worldwide network of distributors and agents to support the international
marketing of its product line.
The company's products and equipment are intended for use by oncologists,
radiologists, urologists, and medical physicists.
Eckert & Ziegler BEBIG employs more than 150 people. The company has been listed
on the Euronext stock exchange since April 1997.
Contact
Paul-Emmanuel Goethals
Investor Relations
Tel.: +32.64.520.808
Email:ir(at)bebig.eu
Website:www.bebig.eu
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: IBt Bebig via Thomson Reuters ONE
[HUG#1525923]
Unternehmensinformation / Kurzprofil:
Datum: 29.06.2011 - 07:46 Uhr
Sprache: Deutsch
News-ID 55937
Anzahl Zeichen: 4063
contact information:
Town:
Seneffe
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 266 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"IBt Bebig Changes Its Name to Eckert & Ziegler BEBIG"
steht unter der journalistisch-redaktionellen Verantwortung von
IBt Bebig (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
